TaiGen Biopharmaceuticals Holdings Limited Stock
Equities
4157
KYG866171005
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15 TWD | -0.99% | -2.60% | -1.32% |
Sales 2022 | 36.23M 1.12M | Sales 2023 | 123M 3.82M | Capitalization | 10.91B 338M |
---|---|---|---|---|---|
Net income 2022 | -237M -7.34M | Net income 2023 | 137M 4.24M | EV / Sales 2022 | 294 x |
Net cash position 2022 | 860M 26.65M | Net cash position 2023 | 963M 29.85M | EV / Sales 2023 | 80.8 x |
P/E ratio 2022 |
-48.5
x | P/E ratio 2023 |
80
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50% |
1 day | -0.99% | ||
1 week | -2.60% | ||
Current month | -2.28% | ||
1 month | -0.33% | ||
3 months | +0.67% | ||
6 months | +1.01% | ||
Current year | -1.32% |
Managers | Title | Age | Since |
---|---|---|---|
Philip Huang
CEO | Chief Executive Officer | - | 18-12-16 |
Richard Lue
DFI | Director of Finance/CFO | - | 16-03-31 |
Ming-Chu Hsu
BRD | Director/Board Member | - | 01-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shou-Chuan Ho
BRD | Director/Board Member | - | 13-04-28 |
Hong Jen Chang
BRD | Director/Board Member | 68 | 13-03-31 |
Sheng Fu Yu
BRD | Director/Board Member | 79 | 19-06-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +2.67% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 15 | -0.99% | 2,398,368 |
24-05-02 | 15.15 | -1.30% | 1,677,726 |
24-04-30 | 15.35 | -1.92% | 1,715,231 |
24-04-29 | 15.65 | +1.62% | 3,141,355 |
24-04-26 | 15.4 | -0.65% | 2,047,624 |
End-of-day quote Taipei Exchange, May 02, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-1.32% | 333M | |
-1.43% | 104B | |
+8.96% | 105B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- 4157 Stock